Duloxetine shows strength in ₩30B antidepressant mkt

By Nho, Byung Chul | translator Kim, Jung-Ju

23.05.13 05:50:42

가나다라 0

Top-line sales for duloxetine KRW 17.7 billion, venlafaxine KRW 12.7 billion

Cymbalta makes ‘KRW 9.7 billion’ and held the unwavering lead... Hanlim and Myung-In Pharm’s generics also show growth

Efexor makes sales of ‘KRW 4.4 billion’... Korea Pharma’s venlafaxine raise KRW 2.8 billion and emerge as a ‘dark horse’ in the market

Last year, top-line sales of the antidepressant duloxetine recorded KRW 17.7 billion, taking a big lead ahead of venlafaxine, which achieved KRW 12.7 billion in sales, and is solidifying its position in the relevant prescription market.

According to drug distribution data, sales of duloxetine drugs grew from KRW 15.5 billion to KRW 17.7 billion from 2019 to 2022, whereas sales of venlafaxine drugs showed a declining trend from KRW 13.1 billion to KRW 12.7 billion.

The contrasting performance of the top two major antidepressant substances in the market is interpreted to be attributed to the difference in their indications.

The duloxetine original, Lilly’s Korea’s Cymbalta

Nho, Byung Chul(sasiman@dailypharm.com)

If you want to see the full article, please JOIN US (click)